vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Vital Farms, Inc. (VITL). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $213.6M, roughly 1.3× Vital Farms, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 7.6%, a 88.7% gap on every dollar of revenue. On growth, Vital Farms, Inc. posted the faster year-over-year revenue change (28.7% vs 9.4%). Over the past eight quarters, Vital Farms, Inc.'s revenue compounded faster (20.2% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Vital Tomosi Dairy Limited is a dairy processing company in Uganda. The company is a joint venture between Vital Capital Fund, "an impact investing fund primarily focused on Sub-Saharan Africa", and "Tomosi Dairy Farms, a Ugandan producer of dairy products".
ACAD vs VITL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $213.6M |
| Net Profit | $273.6M | $16.3M |
| Gross Margin | 90.8% | 35.8% |
| Operating Margin | 6.1% | 10.0% |
| Net Margin | 96.3% | 7.6% |
| Revenue YoY | 9.4% | 28.7% |
| Net Profit YoY | 90.3% | 54.3% |
| EPS (diluted) | $1.61 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $213.6M | ||
| Q3 25 | $278.6M | $198.9M | ||
| Q2 25 | $264.6M | $184.8M | ||
| Q1 25 | $244.3M | $162.2M | ||
| Q4 24 | $259.6M | $166.0M | ||
| Q3 24 | $250.4M | $145.0M | ||
| Q2 24 | $242.0M | $147.4M | ||
| Q1 24 | $205.8M | $147.9M |
| Q4 25 | $273.6M | $16.3M | ||
| Q3 25 | $71.8M | $16.4M | ||
| Q2 25 | $26.7M | $16.6M | ||
| Q1 25 | $19.0M | $16.9M | ||
| Q4 24 | $143.7M | $10.6M | ||
| Q3 24 | $32.8M | $7.4M | ||
| Q2 24 | $33.4M | $16.3M | ||
| Q1 24 | $16.6M | $19.0M |
| Q4 25 | 90.8% | 35.8% | ||
| Q3 25 | 92.2% | 37.7% | ||
| Q2 25 | 92.2% | 38.9% | ||
| Q1 25 | 91.7% | 38.5% | ||
| Q4 24 | 91.6% | 36.1% | ||
| Q3 24 | 92.5% | 36.9% | ||
| Q2 24 | 92.5% | 39.1% | ||
| Q1 24 | 88.8% | 39.8% |
| Q4 25 | 6.1% | 10.0% | ||
| Q3 25 | 12.8% | 10.8% | ||
| Q2 25 | 12.2% | 12.9% | ||
| Q1 25 | 7.9% | 13.4% | ||
| Q4 24 | 59.1% | 7.8% | ||
| Q3 24 | 12.6% | 6.4% | ||
| Q2 24 | 12.6% | 11.6% | ||
| Q1 24 | 7.4% | 16.3% |
| Q4 25 | 96.3% | 7.6% | ||
| Q3 25 | 25.8% | 8.3% | ||
| Q2 25 | 10.1% | 9.0% | ||
| Q1 25 | 7.8% | 10.4% | ||
| Q4 24 | 55.4% | 6.4% | ||
| Q3 24 | 13.1% | 5.1% | ||
| Q2 24 | 13.8% | 11.1% | ||
| Q1 24 | 8.0% | 12.9% |
| Q4 25 | $1.61 | $0.35 | ||
| Q3 25 | $0.42 | $0.36 | ||
| Q2 25 | $0.16 | $0.36 | ||
| Q1 25 | $0.11 | $0.37 | ||
| Q4 24 | $0.86 | $0.23 | ||
| Q3 24 | $0.20 | $0.16 | ||
| Q2 24 | $0.20 | $0.36 | ||
| Q1 24 | $0.10 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $48.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $351.3M |
| Total Assets | $1.6B | $518.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $48.8M | ||
| Q3 25 | $258.0M | $93.8M | ||
| Q2 25 | $253.6M | $108.2M | ||
| Q1 25 | $217.7M | $156.3M | ||
| Q4 24 | $319.6M | $150.6M | ||
| Q3 24 | $155.1M | $149.5M | ||
| Q2 24 | $177.1M | $133.2M | ||
| Q1 24 | $204.7M | $113.8M |
| Q4 25 | $1.2B | $351.3M | ||
| Q3 25 | $917.3M | $331.2M | ||
| Q2 25 | $822.4M | $309.8M | ||
| Q1 25 | $765.2M | $288.9M | ||
| Q4 24 | $732.8M | $269.3M | ||
| Q3 24 | $577.2M | $253.4M | ||
| Q2 24 | $516.7M | $238.4M | ||
| Q1 24 | $464.0M | $213.3M |
| Q4 25 | $1.6B | $518.7M | ||
| Q3 25 | $1.3B | $481.5M | ||
| Q2 25 | $1.2B | $430.8M | ||
| Q1 25 | $1.1B | $376.9M | ||
| Q4 24 | $1.2B | $359.3M | ||
| Q3 24 | $976.9M | $344.7M | ||
| Q2 24 | $914.1M | $320.5M | ||
| Q1 24 | $855.1M | $300.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $5.8M |
| Free Cash FlowOCF − Capex | — | $-32.1M |
| FCF MarginFCF / Revenue | — | -15.1% |
| Capex IntensityCapex / Revenue | — | 17.8% |
| Cash ConversionOCF / Net Profit | -0.18× | 0.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-48.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $5.8M | ||
| Q3 25 | $74.3M | $23.4M | ||
| Q2 25 | $64.0M | $-761.0K | ||
| Q1 25 | $20.3M | $5.3M | ||
| Q4 24 | $40.4M | $14.8M | ||
| Q3 24 | $63.2M | $10.0M | ||
| Q2 24 | $25.0M | $16.1M | ||
| Q1 24 | $29.1M | $23.9M |
| Q4 25 | — | $-32.1M | ||
| Q3 25 | $73.9M | $-10.6M | ||
| Q2 25 | — | $-7.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $-3.4M | ||
| Q3 24 | $63.2M | $6.4M | ||
| Q2 24 | — | $10.5M | ||
| Q1 24 | — | $22.6M |
| Q4 25 | — | -15.1% | ||
| Q3 25 | 26.5% | -5.3% | ||
| Q2 25 | — | -4.1% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | -2.0% | ||
| Q3 24 | 25.2% | 4.4% | ||
| Q2 24 | — | 7.2% | ||
| Q1 24 | — | 15.3% |
| Q4 25 | — | 17.8% | ||
| Q3 25 | 0.1% | 17.1% | ||
| Q2 25 | — | 3.7% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | 0.0% | 2.5% | ||
| Q2 24 | — | 3.8% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | -0.18× | 0.35× | ||
| Q3 25 | 1.03× | 1.43× | ||
| Q2 25 | 2.40× | -0.05× | ||
| Q1 25 | 1.07× | 0.31× | ||
| Q4 24 | 0.28× | 1.40× | ||
| Q3 24 | 1.93× | 1.34× | ||
| Q2 24 | 0.75× | 0.99× | ||
| Q1 24 | 1.76× | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
VITL
| Eggs And Egg Related Products | $205.8M | 96% |
| Butter And Butter Related Products | $7.7M | 4% |
